These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 12669406)

  • 21. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
    Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
    Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
    Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
    Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
    [No Abstract]   [Full Text] [Related]  

  • 23. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
    Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
    J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
    [No Abstract]   [Full Text] [Related]  

  • 24. Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation.
    Vandenberghe P; Boeckx N; Ronsyn E; Decorte R; Verhoef G; Hagemeijer A
    Leukemia; 2003 Feb; 17(2):458-60. PubMed ID: 12592347
    [No Abstract]   [Full Text] [Related]  

  • 25. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term remission of T-lymphoid extramedullary blast crisis of chronic myelogenous leukemia following allogeneic bone marrow transplantation.
    Montefusco E; Mauro FR; Lo Coco F; Rondinelli B; Arcese W; Tabilio A; Monarca B; Alimena G; Mandelli F
    Haematologica; 1990; 75(4):391-3. PubMed ID: 2276682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
    Zonder JA; Schiffer CA
    Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.
    Bogdanić V; Aurer I; Hitrec V; Boban D; Nemet D; Zupancić-Salek S; Labar B
    Haematologica; 1995; 80(4):338-40. PubMed ID: 7590504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
    Salesi N; Bossone G; Della Longa G; Di Cocco B
    Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic myelogenous leukaemia (CML): an update.
    Kumar L
    Natl Med J India; 2006; 19(5):255-63. PubMed ID: 17203680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
    Avery S; Nadal E; Marin D; Olavarria E; Kaeda J; Vulliamy T; Brito Babapulle F; Goldman JM; Apperley JF
    Leuk Res; 2004 May; 28 Suppl 1():S75-7. PubMed ID: 15036946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
    Moser AM; Manor E; Narkis G; Kapelushnik J
    Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
    Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
    Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy of chronic myelogenous leukemia in 2004].
    Hochhaus A; Berger U; Hehlmann R
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
    Mohamed AN; Pemberton P; Zonder J; Schiffer CA
    Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
    Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
    Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
    Breccia M; Nanni M; Mancini F; Russo E; Mecarocci S; Alimena G
    Haematologica; 2004 Apr; 89(4):ECR11. PubMed ID: 15075103
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.